The rise of GPS vulnerability is putting more resilient, atom-based navigational tools on the map. In late September, a Spanish military plane carrying the country’s defense minister to a base in ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Wedbush analyst Martin Fan assumed coverage of Vor Bio (VOR) with a Neutral rating with a price target of $9, up from 40c. The firm notes Vor’s lead candidate telitacicept is a BAFF/APRIL ligand trap ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Vor Biopharma shares fell sharply Tuesday in premarket trading after the company priced its $100 million offering below recent trading prices. Shares traded 31% lower ahead of the morning bell at ...

The navigation pane, located on the far left side of File Explorer, is used to find files, folders, and drives on your Windows 11/10 PC or network. When you set the navigation pane to show or hide in ...

You’re lost. Even worse, there’s no cell signal. The last thing keeping you from fully freaking out is that little blue dot — the universal sign that, somewhere up above, a GPS satellite has eyes on ...

Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept. The shares of ...

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after RemeGen revealed the success of a China phase 3 trial ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Dyson's first robot vacuum ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition. Vor hit reset in May, after nearly a decade of work on blood ...